Robert J. More - 19 Dec 2025 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Reporting relationship: Director
Issuer ticker: TYRA
Reported as of: 19 Dec 2025
Net transaction value: -$250,000
SEC form: 4
Accepted by SEC: 19 Dec 2025, 21:00:04 UTC
Prior SEC filing: 25 Nov 2025
Next SEC filing: 28 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ali D. Fawaz, Attorney-in-Fact

Key filing fact

Robert J. More filed Form 4 for Tyra Biosciences, Inc. (TYRA) on 19 Dec 2025.

Key facts

This page summarizes Robert J. More's Form 4 filing for Tyra Biosciences, Inc. (TYRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Dec 2025, 21:00.

Change

Previous filing in this sequence was filed on 25 Nov 2025.
Current net transaction value: -$250,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001207792 Primary reporting owner

MORE ROBERT J

Relationship: Director
Address: C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD
Signature: /s/ Ali D. Fawaz, Attorney-in-Fact
Signature date: 19 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TYRA transaction

Common Stock

Sale

Transaction value: $250,000
Shares: -10,000
Change %: -0.26%
Price: $25.00
Shares after: 3,823,425
Date: 19 Dec 2025
Ownership: See footnote
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ("APNG II") on June 26, 2025.

Footnote F2

These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.